Evidence map›Paper›PMID 32376736›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2020

Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia.

Koji Matsuo, Rachel S Mandelbaum, Marcia Ciccone, Mahdi Khoshchehreh, Heena Pursuwani, Elise B Morocco, Shinya Matsuzaki, Christina E Dancz, Begum Ozel, Richard J Paulson and 1 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Koji Matsuo *Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA koji.matsuo@gmail.com.ORCID 0000-0002-6232-8701
Rachel S Mandelbaum *Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Marcia CicconeObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Mahdi KhoshchehrehObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Heena PursuwaniObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Elise B MoroccoObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Shinya MatsuzakiObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Christina E DanczObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Begum OzelObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Richard J PaulsonObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Lynda RomanObstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

introductionPrevious studies have suggested that metformin use may enhance the therapeutic effect of progestin therapy for endometrial hyperplasia or malignancy. However, it is not known how the impact of concurrent metformin may be altered by route of progestin therapy, either locally via an intrauterine device or systemically. This study examined the effectiveness of concurrent metformin use and progestin therapy for women with complex atypical hyperplasia stratified by progestin route (systemic vs local).

methodsThis single-institution retrospective study examined consecutive women with complex atypical hyperplasia who received progestin therapy from 2003 to 2018. Time-dependent analyses for complete response rate were performed comparing concurrent metformin users versus non-users in the oral progestin group and in the levonorgestrel-releasing intrauterine device group.

resultsAcross the study cohort (n=245), there were 137 (55.9%) women who responded to progestin therapy. In the oral progestin group (n=176), the median age and body mass index were 36 years and 37.7 kg/m

conclusionIn a predominantly obese population, concurrent metformin may possibly offer treatment benefit when used with the levonorgestrel-releasing intrauterine device.

Indexed as

AdultEndometrial NeoplasmsFemaleHumansHyperplasiaMetforminMiddle AgedObesityProgestinsRetrospective StudiesMetforminProgestinsendometrial hyperplasia

Identifiers

PMID32376736
PMCPMC7521080
OpenAlexW3023252907

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.